The list price of a prescription drug in America is a number the manufacturer invents. No federal agency reviews it. No regulator approves it. No formula governs it. The manufacturer picks a number, publishes it, and the entire system calculates everything else from there.

Most payers never pay that number. Insurers negotiate discounts. Pharmacy benefit managers extract rebates. Hospitals get statutory ceilings. But one group routinely pays at or near the list price: uninsured patients and insured patients in high-deductible plans who haven't met their annual limit. The sticker price is fiction for the system and reality for the people least able to afford it.

The Three Benchmarks That Define Drug Prices

US drug pricing runs on a stack of acronyms. Three matter most: WAC, AWP, and ASP. Each measures something different. None measures what patients actually pay.

WAC: The Starting Point

Wholesale Acquisition Cost is the manufacturer's published list price to wholesalers. It is the foundation of the entire US drug pricing system. Every rebate, discount, and reimbursement formula starts here.

WAC is set unilaterally. The manufacturer decides the number. There is no approval process, no cap, no review board. The FDA does not evaluate pricing. CMS does not negotiate (with limited exceptions under the Inflation Reduction Act). The manufacturer files a price with commercial data services, and the system accepts it.

When media reports say a drug "costs" a certain amount, they almost always mean WAC. When manufacturers announce price increases, they mean increases to WAC. It is the number that moves everything else.

AWP: The Fictional Benchmark

Average Wholesale Price is a published benchmark standardised at 120% of WAC for brand-name drugs. The name implies an average of actual wholesale transactions. It is not. After litigation in the 2000s exposed how disconnected AWP was from real prices, the industry settled on a fixed markup formula.

The pharmaceutical industry's own nickname for AWP is "Ain't What's Paid." Despite this, AWP remains the reimbursement basis in some pharmacy contracts and state Medicaid programs. It persists because the system was built around it, and rebuilding is expensive.

ASP: The Closest to Reality

Average Sales Price is the benchmark Medicare Part B uses to reimburse physician-administered drugs (infusions, injections given in clinics). Unlike WAC, ASP is calculated from actual sales data net of rebates and most discounts. CMS publishes it quarterly with a two-quarter lag.

ASP is the most accurate official measure of what the market actually pays for Part B drugs. But it covers only physician-administered products, not the retail prescriptions most patients pick up at a pharmacy.

Other Benchmarks

NADAC (National Average Drug Acquisition Cost) comes from a CMS weekly survey of roughly 2,500 pharmacies. It captures what pharmacies actually pay on their invoices and is the closest measure of real acquisition cost in the system. State Medicaid programs increasingly use it for reimbursement.

The 340B ceiling price is a statutory discount for safety-net providers: federally qualified health centres, disproportionate share hospitals, and Ryan White HIV/AIDS clinics. It is calculated as Average Manufacturer Price minus the Unit Rebate Amount, typically 25 to 50% below AMP for brand drugs.

The Three Players Who Set Prices

Three players shape what a drug costs. Each operates by different rules, with different incentives.

Manufacturers: Unilateral Power

Drug companies set WAC without external constraint. The standard justification cites R&D costs, therapeutic value, and what competitors charge. In practice, launch prices have climbed steadily. The median new drug launch price exceeded $200,000 per year by 2022, according to a 2023 study in JAMA.

Once a drug is on the market, manufacturers apply annual price increases. Historically these ran 7 to 10% per year. That pace has slowed recently: brand list price growth hit 3.5% in 2025, the lowest in over a decade. But net prices tell a different story. They fell 0.7% in nominal terms and 3.4% after inflation adjustment. For the eighth consecutive year, what manufacturers actually collected per unit went down even as sticker prices went up.

PBMs: The Rebate Negotiators

Pharmacy benefit managers sit between manufacturers and insurers. They negotiate rebates on behalf of health plans, manage formularies (the list of drugs a plan covers), and adjudicate claims at the pharmacy counter. Three PBMs control roughly 80% of the market: CVS Caremark, Express Scripts, and OptumRx.

The incentive structure creates a problem. PBMs negotiate rebates expressed as a percentage of WAC. A higher list price generates a larger rebate in dollar terms, even at the same percentage. A 40% rebate on a $300 drug yields $120. The same percentage on a $100 drug yields $40. PBMs are financially motivated to favour expensive drugs with large rebates over cheaper alternatives with smaller ones.

This dynamic has pushed list prices upward since the early 2000s. Manufacturers compete not on the lowest net price but on the largest rebate. A company offering a lower list price with a smaller rebate can lose formulary placement to a competitor offering a higher list price with a bigger rebate, even when the net cost to the plan is the same.

Insurers: Formulary Tiers and Cost-Sharing

Health insurers set formulary tiers that determine what patients pay at the counter. Tier 1 (generics) carries the lowest copay. Tier 4 or 5 (specialty and non-preferred brands) carries the highest. Placement on a tier is partly clinical, partly financial. Drugs that generate larger rebates get preferred positions.

The critical detail: patient copays and coinsurance (a percentage of the drug's price, rather than a flat fee) are typically calculated on the list price, not the net price after rebates. A patient with 20% coinsurance on a $500 drug pays $100 out of pocket. The insurer may have received a $200 rebate, bringing the effective cost to $300. But the patient's share was calculated before that rebate entered the equation.

The Gross-to-Net Bubble

The gap between what manufacturers list as the price (gross) and what they actually collect after rebates and discounts (net) has been widening for years. The industry calls this the gross-to-net bubble. It is the central distortion in American drug pricing.

Rebates and discounts reduce brand drug invoice prices by 37 to 52%, according to IQVIA's 2024 data. In some therapeutic classes, particularly insulin, rebates exceed 80% of the list price. In those cases, for every dollar on the sticker, the manufacturer keeps less than 20 cents. The rest flows to PBMs, insurers, and other intermediaries as rebates, fees, and administrative charges.

Why It Matters

The bubble creates a system where nobody wants to lower list prices. Manufacturers need high WAC to offer the large rebates PBMs demand. PBMs need large rebates to demonstrate value to plan sponsors. Insurers build their benefit designs around the rebate revenue. Lowering the list price would collapse the economics all three parties depend on.

Patients bear the cost of this arrangement. Those with coinsurance pay a percentage of the inflated list price. Those in the deductible phase of high-deductible plans pay the full list price until they hit their limit. Uninsured patients face list price with no rebate offset at all.

The Humalog Case

Eli Lilly's insulin Humalog illustrates the paradox. Between 2015 and 2019, Humalog's list price rose 27%. Over the same period, its net price fell 14%. The list price and the actual price moved in opposite directions.

The entire list price increase went to rebates. Lilly collected less per unit while charging more on paper. But patients with coinsurance or high deductibles paid based on the rising list price. Their costs tracked the fiction, not the reality.

This was not unique to Humalog. Across four leading insulin products between 2012 and 2019, gross sales doubled from $13 billion to $27 billion while net sales dropped 40%, from $8 billion to $5 billion. Price concessions exceeded 80% by 2019.

Why the US Pays More Than Everyone Else

US drug prices average 278% of those in 33 OECD countries, according to a 2022 RAND Corporation study. For brand-name drugs, the gap widens to 422% at gross prices and 322% even after adjusting for rebates. Americans pay more after discounts than other countries pay at full price.

The exception is generics. US generic prices run at 67% of the OECD average. Competition works in the generic market. The brand market is a different story.

The US is the only OECD country that does not regulate or negotiate drug prices at the national level. Every other wealthy democracy uses some combination of government price regulation, health technology assessment, international reference pricing, or direct negotiation with manufacturers. The US does none of these for the commercial market.

Total US pharmaceutical spending reached $487 billion in 2024, up 11.4% from the prior year. Per capita, Americans spent $1,713 on prescription drugs in 2023. The OECD average was $766. Specialty drugs, which account for roughly 2% of prescriptions, drive approximately 50% of total spending.

What Is Changing

After decades of inaction, federal policy is moving. The changes are real but limited.

Medicare Drug Price Negotiation

The Inflation Reduction Act of 2022 gave Medicare the authority to negotiate prices directly with manufacturers for the first time. The program started with 10 high-spending Part D drugs in 2026, achieving discounts of 38 to 79% off list prices. It expands to 15 drugs in 2027, another 15 in 2028, and up to 20 per year after that.

Separately, the IRA capped Medicare Part D out-of-pocket costs at $2,000 per year, effective 2025. For the roughly 1.4 million beneficiaries who previously spent more than that, the cap is the single most immediate change.

The limits of negotiation are significant. It covers only Medicare, not the commercial market. The number of drugs is small relative to the thousands on the market. The negotiated prices, while substantially lower than US list prices, remain 1.6 to 3.9 times international averages. Medicare chose not to use international prices as a benchmark.

PBM Reform

The Consolidated Appropriations Act of 2026 is the most comprehensive federal PBM legislation to date. Starting in 2028, PBM compensation must be limited to flat-dollar service fees at fair market value, eliminating the percentage-of-WAC model that rewards high list prices. By 2029, manufacturers must pass through 100% of rebates to ERISA employer plans. Spread pricing is banned for these plans.

The structural shift matters. Flat-fee compensation removes the financial incentive for PBMs to prefer expensive drugs. If the fee is $5 per claim regardless of the drug's price, the PBM has no reason to favour a $500 drug over a $50 one.

Price Growth Is Slowing

Brand list price growth of 3.5% in 2025 is the lowest in more than a decade. Manufacturers appear to be moderating increases in anticipation of potential selection for Medicare negotiation. Net prices are declining in real terms for the eighth consecutive year. The gross-to-net bubble continues to expand, but the direction of policy pressure is clear.

These reforms do not fix the system. They constrain specific parts of it. The commercial market remains largely unregulated. Launch prices for new drugs continue to climb. The fundamental structure, where the manufacturer sets a price and the rest of the system negotiates around it, has not changed.